Whether filgotinib is included in the medical insurance reimbursement policy and related instructions

Filgotinib is a selective JAK1 inhibitor, mainly used to treat autoimmune diseases such as moderate to severe active rheumatoid arthritis. Although the drug has been approved and put into clinical use in many countries such as Europe and the United States, filgotinib has not yet received official marketing approval from the National Food and Drug Administration (NMPA) in mainland China. Therefore, it has not yet been included in China's national medical insurance catalog, and patients cannot be reimbursed through medical insurance, and all costs must be borne at their own expense.

Since it has not yet been launched in China, filgotinib is not covered by medical insurance negotiations, which means that even if the patient does have indications, he cannot reduce the financial burden through medical insurance. Domestic hospitals and pharmacies cannot prescribe the drug. If patients need to use it, they can only rely on overseas drug purchase channels. There are currently two main versions on the market: EU-approved original drugs and relatively cheap generic drugs. Among them, the European version of the original drug (200mg30tablets) is priced at more than 10,000 yuan per box, which is expensive; while the generic version (100mg30tablets) produced by Laos Lucius Pharmaceutical Company is priced at about 900 yuan per box and is more popular among patients under great financial pressure.

Although generic drugs have more advantages in terms of cost, patients should pay attention to the quality and formality of the drugs when purchasing. Since filgotinib does not fall under the management of the domestic drug regulatory system, and its generic drugs have not been certified by the State Food and Drug Administration, patients need to obtain the drug through legal and compliant cross-border medical or international pharmacy channels and avoid purchasing through personal purchasing or informal platforms to reduce the risk of buying counterfeit or inferior drugs. Before use, you should also fully consult your doctor to ensure the safety and adaptability of the medication.

To sum up, filgotinib has not yet been approved for marketing in my country, so it is not covered by medical insurance reimbursement. If patients need to use this medicine, they should obtain it from foreign formal channels, choose the appropriate version based on their own condition and financial ability, and use it under the guidance of a professional doctor. In the future, if the drug is marketed in China and included in medical insurance, it is expected to provide a more economical and convenient treatment option for the majority of patients.

Reference materials:https://www.drugs.com/